Vestmark Advisory Solutions Inc. Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

Vestmark Advisory Solutions Inc. purchased a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 123,447 shares of the company’s stock, valued at approximately $4,550,000.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Twist Bioscience by 3.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock worth $8,965,000 after acquiring an additional 14,511 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Twist Bioscience by 559.5% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock worth $2,159,000 after purchasing an additional 90,413 shares during the last quarter. Dark Forest Capital Management LP raised its position in shares of Twist Bioscience by 121.3% during the 3rd quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock worth $597,000 after purchasing an additional 16,142 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $451,000. Finally, Citigroup Inc. boosted its stake in shares of Twist Bioscience by 94.1% during the third quarter. Citigroup Inc. now owns 264,204 shares of the company’s stock valued at $5,353,000 after acquiring an additional 128,098 shares during the last quarter.

Twist Bioscience Price Performance

Shares of TWST traded up $9.20 during midday trading on Friday, hitting $41.21. The company had a trading volume of 4,458,430 shares, compared to its average volume of 909,964. Twist Bioscience Co. has a 52 week low of $11.81 and a 52 week high of $43.21. The company’s 50 day moving average price is $34.03 and its 200 day moving average price is $30.96.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 30.81% and a negative net margin of 69.24%. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same quarter last year, the business posted ($1.06) EPS. Twist Bioscience’s quarterly revenue was up 25.1% compared to the same quarter last year. Equities analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the subject of a number of analyst reports. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays raised their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday. Scotiabank boosted their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th. Finally, Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $41.67.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now directly owns 516,409 shares in the company, valued at approximately $19,329,188.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the transaction, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Insiders sold a total of 13,211 shares of company stock worth $449,573 in the last three months. 3.92% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.